Recursion Pharmaceuticals (NASDAQ:RXRX) PT Lowered to $15.00 at Needham & Company LLC
Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its price target cut by Needham & Company LLC from $17.00 to $15.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, KeyCorp upped their price objective on shares of Recursion Pharmaceuticals from $12.00 to […]
More Stories
Legal & General Group Plc Decreases Holdings in AtriCure, Inc. (NASDAQ:ATRC)
Legal & General Group Plc lowered its holdings in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 1.4% during the fourth...
RLX Technology Inc. (NYSE:RLX) Shares Sold by Legal & General Group Plc
Legal & General Group Plc trimmed its holdings in shares of RLX Technology Inc. (NYSE:RLX – Free Report) by 47.6%...
Delek US Holdings, Inc. (NYSE:DK) Stock Position Reduced by Legal & General Group Plc
Legal & General Group Plc decreased its holdings in shares of Delek US Holdings, Inc. (NYSE:DK – Free Report) by...
11,400 Shares in SiTime Co. (NASDAQ:SITM) Acquired by Renaissance Technologies LLC
Renaissance Technologies LLC acquired a new stake in shares of SiTime Co. (NASDAQ:SITM – Free Report) in the fourth quarter,...
Cerity Partners LLC Lowers Stock Holdings in Sasol Limited (NYSE:SSL)
Cerity Partners LLC lessened its holdings in shares of Sasol Limited (NYSE:SSL – Free Report) by 55.4% during the fourth...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Legal & General Group Plc
Legal & General Group Plc decreased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 3.3%...